Skip to main content
. 2016 Jan 28;7(8):9288–9295. doi: 10.18632/oncotarget.7063

Figure 2. Example of additional value of [68Ga]Pentixafor-PET in an SCLC patient.

Figure 2

Display of maximum intensity projections (upper row) and transaxial images (lower row) of both CXCR4- and [18F]FDG-PET/CT (interval between both scans, 6 days) in a patient with recurrent SCLC (patient #4). [68Ga]Pentixafor-PET demonstrates more intense tracer retention in various tumor manifestations including mediastinal lymph nodes (arrows; insert: corresponding contrast-enhanced transaxial CT).